Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629596 | 0.82 | CYP19A1 (0.46) | BRD4CCNB2CDK1CDK4CCNB1 | |
| SCHEMBL19946528 | 0.81 | MAPT (0.59) | BRD4L3MBTL1TDP1MAPTGAA | |
| Niacin SCHEMBL28302819 | 0.81 | LMNA (0.56) | BRD4TDP1MAPTMAPK1APP | |
| SCHEMBL23592012 | 0.80 | POLB (0.50) | L3MBTL1MAPTGAAPPIA | |
| SCHEMBL30954778 | 0.79 | L3MBTL1 (0.45) | BRD4CCNB2CDK1CDK4CCNB1 | |
| SCHEMBL10917600 | 0.79 | NR4A2 (0.54) | L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2169810 | 0.79 | L3MBTL1 (0.45) | BRD4CCNB2CDK1CDK4CCNB1 | |
| SCHEMBL10919602 | 0.79 | MAPT (0.42) | BRD4CCNB2CDK1CDK4CCNB1 | |
| SCHEMBL7525333 | 0.79 | ALDH1A1 (0.57) | TSHRL3MBTL1MAPTGAANPC1 | |
| SCHEMBL10410172 | 0.78 | BRD4 (0.43) | BRD4TSHRCCNB2CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263623-B2 | Triazol derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263623-B2 | Triazol derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-8017612-B2 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | PFIZER INC | 2010-01-14 | — | — | US | disclosed |
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | PFIZER INC | 2010-01-14 | — | — | US | disclosed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | TSLP, IL5, EPX | BRD4 696/4885TSHR 1834/4885CCNB2 2563/4885 |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | BRD4 127/4885TSHR 3775/4885CCNB2 3818/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | BRD4 416/4885TSHR 4735/4885CCNB2 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.